PDCD1 and hepatocellular carcinoma: Total prior data for HCC (both HBV+ and HBV−) indicated that dermatological toxicity was common but mild in anti–PD-1/PD-L1 therapy (Table 2), and the symptoms could be controlled by classical topical corticosteroid creams, peroral antipruritics or intravenous corticosteroid in more-severe cases.